Frank Rimerman Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Frank Rimerman Advisors's VRTX Position: Q2 2026 in Review
Frank Rimerman Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 1.7% in Q2 2026, buying an estimated $24.8K and bringing the position to 3,373 shares worth $1.68M. The position accounts for 0.09% of the portfolio, ranked #165.
Frank Rimerman Advisors first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.49M in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Frank Rimerman Advisors held 3,373 shares of Vertex Pharmaceuticals worth $1.68M as of Q2 2026.
- Frank Rimerman Advisors bought 56 Vertex Pharmaceuticals shares in Q2 2026, an estimated $24.8K.
- Vertex Pharmaceuticals made up 0.09% of Frank Rimerman Advisors's portfolio in Q2 2026, its #165 holding.
- Frank Rimerman Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
- Frank Rimerman Advisors's Vertex Pharmaceuticals position peaked at $2.49M in Q2 2024.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Frank Rimerman Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.